SENSEX NIFTY

Trastuzumab

Jun 04, 2016 at 15:30 | Source: PTI
Global pharma major Mylan Inc, and Biocon have confirmed the efficacy and safety of MYL-1401O, a proposed biosimilar trastuzumab co-developed by the firms, incomparison to Roche's branded Herceptin used for treatment of cancer
May 24, 2016 at 10:11 | Source: CNBC-TV18
These market filings have a market opportunity of USD 40 billion. In particular, Japan offers a market potential of USD 150 million for its insulin product Glargine, says Biocon's Chairman and Managing Director.
Apr 26, 2016 at 20:00 | Source: PTI
Biotechnology firm Biocon today said its product portfolio will not be affected by an order of the Delhi High Court that prevented the company from calling its breast cancer medicine Trastuzumab as a biosimilar of Roche's Herceptin.
Apr 05, 2016 at 10:41 | Source: Moneycontrol.com
It believes that Biocon's (and its partner Mylan) four potential product filings each in the US and EU would add credibility to its pipeline and bring market recognition. Emerging market monetisation is under way, but the US and EU opportunities will take at least two years, according to report.
Sep 15, 2015 at 16:45 | Source: PTI
GBR 1302, a bi-specific monoclonal antibody, is an artificial protein that is composed of fragments of two different monoclonal antibodies and consequently binds two different types of antigens.
Feb 07, 2014 at 22:27 | Source: CNBC-TV18
The Delhi High Court (HC) has thrown a wrench into plans of Biocon and Mylan to market a breast cancer drug that goes by the scientific name Trastuzumab.
Feb 04, 2014 at 09:59 | Source: PTI
The company's subsidiary Mylan Pharmaceuticals Pvt Ltd has launched the world's first trastuzumab biosimilar, which will be marketed by Mylan under the brand name Hertraz Herceptin, a company statement said.
Jan 18, 2014 at 16:21 | Source: Reuters
Bangalore-based Biocon jointly developed biosimilar trastuzumab, which received the Indian drug regulator's marketing approval in November, with US-based Mylan Inc.
Nov 26, 2013 at 14:42 | Source: Moneycontrol.com
Biocon has received marketing authorization from the Drugs Controller General of India for its Biosimilar Trastuzumab being developed jointly with Mylan, for treatment of Her 2+ metastatic breast cancer.
Messages on Trastuzumab »

sanecounsel

Platinum Member

138 Followers

Biocon  

the outcome of the Delhi High Court case brought by Roche against Biocon and Mylan in February gains significance. Roche has alleged that Biocon/Mylan has misrepresented its drugs as a biosimilar of its bestselling breast cancer drug, Trastuzumab (Herceptin), without having undergone the required

10.04 AM Jul 8th 2014

namo8081

New Member

3 Followers

Biocon  

biocon will be selling trastuzumab and glargine in emerging market and rh insulin in EM and EU both.therefore thise who r holding this stock shd plan their trade accordingly. exit at 22-25 p e and reenterbelow 20

12.31 PM Apr 4th 2014

unseenvalue

Gold Member

298 Followers

Biocon  

Biocon should be 10X in next 3 years to compensate for the pain over these years. Unless it delivers against all potential triggers (ItolizuMab, IN105, TrastuzuMab etc) over the next 2/3 years - i for one can`t see 4000 on the screen. Can you Stocktin, Akrmr ?

1.38 PM Apr 3rd 2014

srikanth031
086

Gold Member

183 Followers

Biocon  

trastuzumab. The company was, however, confident that the injunction limiting promotional activities would not stand in Court, once they were heard.

12.32 PM Feb 10th 2014

sanecounsel

Platinum Member

138 Followers

Biocon  

version of Trastuzumab, in the Indian market until the disposal of the present suit, and also sought an injunction restraining the said defendants from relying upon or otherwise referring to HERCEPTIN®, HERCLONTM or BICELTIS® or any data relating to Trastuzumab marketed as HERCEPTIN®, HERCLONTM

10.48 PM Feb 8th 2014

srikanth031
086

Gold Member

183 Followers

Biocon  

. “It is an extremely shocking, but not unexpected development. This proceeding is an attempt by Roche to protect their market monopoly and prevent Indian patients from accessing a more affordable trastuzumab,” Biocon said in a statement

1.50 PM Feb 8th 2014

Web Messenger

Platinum Member

356421 Followers

Biocon  

Source:Economic Times - NEW DELHI: Biocon`s launch of the world`s first bio-similar of Trastuzumab, a critical breast cancer drug, is unlikely to benefit patients in a big way if the company sticks to the prices it has indicated, claimed health activists on Monday. They allege that Roche, which

1.54 PM Jan 21st 2014

Neha-Diwan

Platinum Member

5643 Followers

Biocon  

Biocon shines on introducing world’s first biosimilar trastuzumab `CANMAb`.

12.17 PM Jan 20th 2014

BSE/NSE Announcer

Platinum Member

15254 Followers

Biocon  

Biocon Limited has informed the Exchange regarding a press release dated January 18, 2014, titled"Biocon introduces CANMAb - Worlds First Biosimilar Trastuzumab for Treating Breast Cancer in India".

10.28 AM Jan 20th 2014

BSE/NSE Announcer

Platinum Member

15254 Followers

Biocon  

Biocon Ltd has informed BSE regarding a Press Release dated January 18, 2014 titled "Biocon introduces CANMAb™ - Worlds First Biosimilar Trastuzumab for Treating Breast Cancer in India".

12.52 PM Jan 18th 2014

Explore Moneycontrol

Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.